- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
March 26, 2024Ronald Schutz, Brendan Johnson Named to Forbes Top 200 Lawyers in the United States
-
March 21, 2024Robins Kaplan Firm Members Appointed to Law360 Editorial Boards
-
March 20, 2024Brandon Vaughn Inducted into The International Society of Barristers
-
April 5, 2024Mass Torts Made Perfect
-
April 17, 2024American Antitrust Institute Virtual CLE Lunch & Learn
-
May 2-3, 2024ACI Advanced Forum on Managed Care Disputes and Litigation
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
March 2024Do We Have to Share That Information? Attorney-Client Privilege in the Multi-Entity Context
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
ANDA Approvals
Winter 2012
Approval Date |
Reference Listed Drug |
Generic Drug Name |
NDA Holder |
ANDA Applicant |
10/1/2012 | Prozac | Fluoxetine Hydrochloride | Eli Lilly and Co | Heritage Pharms |
10/1/2012 | Duoneb | Albuterol Sulfate and Ipratropium Bromide | Dey | Ritedose Corp |
10/3/2012 | Trileptal | Oxcarbazepine | Novartis | Roxane |
10/3/2012 | Avapro | Irbesartan | Sanofi Aventis US | Macleods Pharms |
10/5/2012 | Intuniv | Guanfacine Hydrochloride | Shire | Actavis Elizabeth |
10/10/2012 | Plavix | Clopidogrel Bisulfate | Sanofi Aventis US | Zydus Pharms USA |
10/11/2012 | Idamycin PFS | Idarubicin Hydrochloride | Pharmacia and Upjohn | Onco Therapies |
10/11/2012 | Avita | Tretinoin | Mylan | Precision Dermat |
10/12/2012 | Avapro | Irbesartan | Sanofi Aventis US | Watson Labs |
10/12/2012 | Sanctura XR | Trospium Chloride | Allergan | Watson Labs |
10/15/2012 | Avapro | Irbesartan | Sanofi Aventis US | Roxane |
10/15/2012 | Avalide | Irbesartan and Hydrochlorothiazide | Sanofi Aventis | Roxane |
10/15/2012 | Avalide | Irbesartan; Hydrochlorothiazide | Sanofi Aventis | Roxane |
10/15/2012 | Avapro | Irbesartan | Sanofi Aventis US | Alembic Pharms |
10/15/2012 | Avalide | Irbesartan and Hydrochlorothiazide | Sanofi Aventis | Alembic |
10/15/2012 | Requip XL | Ropinirole Hydrochloride | SmithKline Beecham | Mylan |
10/15/2012 | Avapro | Irbesartan | Sanofi Aventis US | Apotex |
10/15/2012 | Avalide | Irbesartan and Hydrochlorothiazide | Sanofi Aventis | Apotex |
10/15/2012 | Avapro | Irbesartan | Sanofi Aventis US | Lupin |
10/16/2012 | Carbatrol | Carbamazepine | Shire | Teva |
10/16/2012 | Fludarabine Phosphate | Fludarabine Phosphate | Hospira | Onco Therapies |
10/16/2012 | Neurontin | Gabapentin | Pfizer Pharms | Invagen Pharms |
10/17/2012 | Nordette-28 | Kurvelo | Teva Branded Pharm | Lupin |
10/18/2012 | Atracurium Besylate and Atracurium Besylate Preservative Free | Atracurium Besylate | Bedford | Hospira |
10/18/2012 | Atracurium Besylate and Atracurium Besylate Preservative Free | Atracurium Besylate Preservative Free | Bedford | Hospira |
10/18/2012 | Provigil | Modafinil | Cephalon | Alembic |
10/22/2012 | Avalide | Irbesartan and Hydrochlorothiazide | Sanofi Aventis | Watson Labs |
10/22/2012 | Grifulvin V | Griseofulvin | Valeant Luxembourg | Sigmapharm Labs |
10/22/2012 | GRIS-PEG | Griseofulvin, Ultramicrosize | Pedinol | Sigmapharm Labs |
10/23/2012 | Seasonale | Levonorgestrel and Ethinyl Estradiol | Teva Branded Pharm | Lupin |
10/23/2012 | Fenofibrate (Micronized) | Fenofibrate (Micronized) | Teva | Mylan |
10/24/2012 | Tofranil | Imipramine Hydrochloride | Mallinckrodt | Excellium |
10/24/2012 | Aricept | Donepezil Hydrochloride | Eisai | Zydus Pharms USA |
10/24/2012 | Tretinoin | Tretinoin | Barr Labs | Anchen Pharms |
10/26/2012 | Actos | Pioglitazone Hydrochloride | Takeda Pharms USA | Watson Labs |
10/26/2012 | Mirapex | Pramipexole Dihydrochloride | Boehringer Ingelheim | Aurobindo Pharma |
11/1/2012 | Provigil | Modafinil | Cephalon | Carlsbad |
11/1/2012 | Keppra XR | Levetiracetam | UCB | Sandoz |
11/2/2012 | Symbyax | Olanzapine and Fluoxetine Hydrochloride | Eli Lilly and Co | Par Pharm |
11/6/2012 | Ovcon-35 | Norethindrone and Ethinyl Estradiol | Warner Chilcott | Vintage Pharms |
11/6/2012 | Revatio | Sildenafil Citrate | Pfizer | Apotex Corp |
11/6/2012 | Revatio | Sildenafil Citrate | Pfizer | Torrent Pharms |
11/6/2012 | Revatio | Sildenafil Citrate | Pfizer | Watson Labs |
11/6/2012 | Revatio | Sildenafil Citrate | Pfizer | Dr Reddy's Labs |
11/7/2012 | Acetadote | Acetylcysteine | Cumberland Pharms | Innopharma |
11/8/2012 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | Bedford | Alvogen |
11/8/2012 | Protonix IV | Pantoprazole Sodium | Wyeth Pharms | Akorn |
11/9/2012 | Zanaflex | Tizanidine Hydrochloride | Acorda | Mylan |
11/9/2012 | Revatio | Sildenafil Citrate | Pfizer | Mylan |
11/14/2012 | Avapro | Irbesartan | Sanofi Aventis US | Cipla |
11/16/2012 | Symbyax | Olanzapine and Fluoxetine Hydrochloride | Lilly | Sandoz |
11/16/2012 | Ultram | Tramadol Hydrochloride | Janssen Pharms | IPCA Labs |
11/19/2012 | Prilosec | Omeprazole | AstraZeneca | Zydus Pharms USA |
11/19/2012 | Roxicodone | Oxycodone Hydrochloride | Mallinckrodt | Aurolife Pharma |
11/19/2012 | Vivactil | Protriptyline Hydrochloride | Odyssey Pharms | Epic Pharma |
11/19/2012 | Solodyn | Minocycline Hydrochloride | Medicis | Aurobindo Pharma |
11/20/2012 | Stalevo 200 | Carbidopa, Levodopa and Entacapone | Orion Pharma | Wockhardt |
11/20/2012 | Plavix | Clopidogrel Bisulfate | Sanofi Aventis US | Wockhardt |
11/21/2012 | Wellbutrin XL | Bupropion Hydrochloride | Valeant Intl | Wockhardt |
11/26/2012 | Luxiq | Betamethasone Valerate | Stiefel | Cobrek Pharms |
11/26/2012 | Ifosfamide | Ifosfamide | Teva Parenteral | Onco Therapies |
11/27/2012 | Detrol | Tolterodine Tartrate | Pharmacia and Upjohn | Mylan |
11/28/2012 | Requip | Ropinirole Hydrochloride | GlaxoSmithKline | Orchid Healthcare |
11/28/2012 | Benztropine Mesylate | Benztropine Mesylate | USL Pharma | Excellium |
11/28/2012 | Cefadroxil | Cefadroxil | Lupin | Hikma Pharms |
11/28/2012 | Zanaflex | Tizanidine Hydrochloride | Acorda | Unichem Labs |
11/29/2012 | Cytomel | Liothyronine Sodium | King Pharms | Sigmapharm Labs |
11/30/2012 | Dexedrine | Dextroamphetamine Sulfate | Corepharma | Actavis Elizabeth |
12/4/2012 | Atacand HCT | Candesartan Cilexetil and Hydrochlorothiazide | AstraZeneca | Mylan |
12/4/2012 | Atacand HCT | Candesartan Cilexetil and Hydrochlorothiazide | AstraZeneca | Apotex |
12/7/2012 | Apresoline | Hydralazine Hydrochloride | Novartis | Alkem Labs |
12/7/2012 | Cardizem CD | Diltiazem Hydrochloride | Valeant Intl | Actavis |
12/7/2012 | Tricor | Fenofibrate | Abbvie | Mylan |
12/11/2012 | Novantrone | Mitoxantrone Hydrochloride | EMD Serono | Onco Therapies |
12/12/2012 | Risperdal | Risperidone | Janssen Pharms | Tris Pharma |
12/14/2012 | Seroquel | Quetiapine Fumarate | AstraZeneca | Sandoz |
12/14/2012 | Aricept ODT | Donepezil Hydrochloride | Eisai Inc | Macleods Pharms |
12/14/2012 | Ultracet | Tramadol Hydrochloride and Acetaminophen | Janssen Pharms | Micro Labs India |
12/14/2012 | Qualaquin | Quinine Sulfate | Mutual Pharm Co Inc | Mylan |
12/14/2012 | Ammonia N 13 | Ammonia N 13 | Feinstein | Houston Cyclotron |
12/17/2012 | Ziagen | Abacavir Sulfate | VIIV Healthcare | Aurobindo Pharma |
12/17/2012 | Ziagen | Abacavir Sulfate | VIIV Healthcare | Apotex |
12/17/2012 | Pepcid | Famotidine | Salix Pharms | Novel Labs |
12/18/2012 | Yasmin | Drospirenone and Ethinyl Estradiol | Bayer Healthcare | Lupin |
12/18/2012 | Prevacid | Lansoprazole | Takeda Pharms USA | Natco Pharma |
12/18/2012 | Singulair | Montelukast Sodium | Merck | Mylan |
12/27/2012 | Lysteda | Tranexamic Acid | Ferring Pharms | Watson Labs |
12/31/2012 | Maxalt | Rizatriptan Benzoate | Merck | Mylan |
12/31/2012 | Maxalt | Rizatriptan Benzoate | Merck | Sandoz |
12/31/2012 | Antabuse | Disulfiram | Odyssey Pharms | Vintage Pharms |
12/31/2012 | Maxalt | Rizatriptan Benzoate | Merck | Natco Pharma |
12/31/2012 | Maxalt | Rizatriptan Benzoate | Merck | Glenmark Generics |
12/31/2012 | Maxalt | Rizatriptan Benzoate | Merck | Mylan |
12/31/2012 | Maxalt | Rizatriptan Benzoate | Merck | Sun Pharma Global |
12/31/2012 | Maxalt | Rizatriptan Benzoate | Merck | Apotex Corp |
12/31/2012 | Maxalt | Rizatriptan Benzoate | Merck | Aurobindo Pharma |
GENERICally Speaking Winter 2012
Related Publications
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.